International Scholarly Research Notices / 2013 / Article / Tab 1

Research Article

The Role of 39 Psoriasis Risk Variants on Age of Psoriasis Onset

Table 1

Meta-analysis of associations between 39 selected SNPs and psoriasis age of onset in three case cohorts.a

Nearby geneRs_idRisk allele of psoriasis/effect allele of age onset _GAIN _WashU/UCSF _UCSFBeta for effect allele of age onset _heterogeneityMeta- valueFDR_ value _NPF

HLA-CHLA-Cw6 0.0005 −0.6180.73
HLA-Crs10484554T/T 0.01670.000016−0.3800.39 <0.0001
HLA-Crs12191877T/T 0.01740.000018−0.3720.39 <0.0001
IFIH1rs17716942T/T0.00140.06680.464−0.2010.090.0020.0280.94
HLA-Crs13191343T/T0.00250.9000−1−0.1880.220.0060.054
LCE3B-LCE3Crs4112788G/G0.00740.82990.8248−0.0990.370.0210.166
FBXL19rs10782001G/A0.03660.9682−1−0.0850.370.0590.37
SDC4rs1008953C/C0.18760.1478−10.1040.470.0690.37
FBXL19rs12924903A/G0.05740.8552−1−0.0740.340.0990.37
TRAF3IP2rs240993T/C0.06590.9254−1−0.0770.400.1020.37
IL23Rrs11209026G/G0.30620.62840.1364−0.1630.650.1040.37
IL12Brs2546890A/G0.06300.8726−10.0740.360.1040.37
IL12Brs12188300T/T0.05620.5824−1−0.1100.200.1260.409
IL12Brs6887695G/G0.12300.96130.73260.0650.790.1550.466
IL23Rrs1004819—/A0.36570.3654−1−0.0590.660.2300.641
IL12Brs953861G/A0.17770.8474−10.0610.450.2580.672
RPS26rs12580100A/G−10.3151−10.164−10.3150.768
TRAF3IP2rs13210247G/G0.63190.0106−1−0.0520.010.4800.985
IL28RArs4649203A/A0.44290.9925−1−0.0390.730.4930.985
NFKBIArs8016947G/G0.24240.1851−1−0.0260.090.5720.985
TRAF3IP2rs33980500T/T0.51990.0131−1−0.0450.010.5730.985
IL12Brs3212227T/G0.70460.73320.87640.0300.990.6060.985
RNF114rs2235617C/G0.99220.99540.2331−0.0190.550.6400.985
IL12Brs3213094C/T0.75990.72160.87640.0260.980.6440.985
RELrs702873C/T0.54960.8308−1−0.0190.650.6580.985
TRAF3IP2rs458017C/C0.29330.0073−1−0.0340.0040.6620.985
IL23Ars2066808A/G0.36000.22950.05120.0400.050.6800.985
TNIP1rs1024995C/C0.72060.1018−1−0.0270.100.6900.985
TRAF3IP2rs13190932A/A0.44340.0415−1−0.0210.030.7910.985
Noners6809854G/G0.63100.0975−10.0140.090.7940.985
TRAF3IP2rs13196377A/G0.39150.0396−10.0190.030.8120.985
NOS2rs4795067G/G0.78160.2546−1−0.0090.250.8440.985
RNF114rs495337G/A0.84240.9978−10.0080.930.8560.985
IL13rs20541G/G0.79180.89790.9620.0100.970.8570.985
NFKBIArs12586317T/C0.74870.7428−10.0080.670.8780.985
ERAP1rs27524A/G0.82400.8969−10.0070.830.8840.985
TYK2rs280519A/G0.58670.2155−10.0040.180.9390.992
TNIP1rs17728338A/A0.78050.60410.7386−0.0050.800.9420.992
TNFAIP3rs610604G/T0.89970.91780.7863−0.0020.950.9670.992
TYK2rs12720356A/C0.72750.5667−10.0010.500.9920.992

FDR_ : false discovery rate adjusted value based on 39 selected SNPs. In total, 898, 182, 418, and 489 psoriasis cases were included in the GAIN, WashU/UCSF, UCSF, and NPF case cohorts, respectively; for certain SNPs that were imputed with low confidence (proper_info < 0.5 for rs12580100) in GAIN cohort or were not genotyped in UCSF case cohort, their information (denoted as = “−1”) was not included in the corresponding meta-analysis; Cochran's statistic was used to examine the heterogeneity.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.